Ascierto PA et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): A randomized, three-arm, open-label Phase II trial. J Clin Oncol 2023;41(2):212-21. Abstract
Atkins MB et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol 2023;41(2):186-97. Abstract
Baramidze A et al. A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma. ASCO 2023;Abstract TPS9602.
Bhatia S et al. Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic merkel cell carcinoma (MCC) (CheckMate 358). ASCO 2023;Abstract 9506.
Carvajal RD et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: A phase 2 trial. Nat Med 2022;28(11):2364-73. Abstract
Dummer R et al. COLUMBUS 5-year update: A randomized, open-label, Phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. J Clin Oncol 2022;40(36):4178-88. Abstract
Gross ND et al. Neoadjuvant cemiplimab for Stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med 2022;387(17):1557-68. Abstract
Haanen J et al. Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab (IPI) for advanced melanoma: Results from a multicenter, randomized phase III trial. ESMO 2022;Abstract LBA3.
Hamid O et al. Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. ASCO 2023;Abstract 9501.
Hamid O et al. Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel). ESMO 2022;Abstract 790MO.
Hamid O et al. Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors. ESMO 2022;Abstract 728O.
Hanna et al. Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1. ASCO 2023;Abstract 9519.
Hodi FS et al. Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067. ASCO 2023;Abstract 9542.
Khattak MA et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. ASCO 2023;Abstract LBA9503.
Kjeldsen JW et al. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med 2021;27(12):2212-23. Abstract
Lewis KD et al. Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a Phase 2 open-label clinical trial. EADO 2023;Abstract HSR23-097.
Long GV et al. Adjuvant therapy with nivolumab versus placebo in patients with stage IIB/C melanoma (CheckMate 76K). SKIN 2023;7(2):s163. Abstract
Luke JJ et al. Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. ASCO 2023;Abstract LBA9505.
Middleton MR et al. Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). ASCO 2022;Abstract 104.
Migden MR et al. Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3. ESMO 2022;Abstract 814P.
Olson D et al. A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma. ASCO 2023;Abstract TPS9607.
O’Malley D et al. Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers. SITC 2021;Abstract 492.
Panella TJ et al. A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma. ASCO 2023;Abstract TPS9598.
Patel SP et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med 2023;388(9):813-23. Abstract
Rohaan MW et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med 2022;387(23):2113-25. Abstract
Sarnaik A et al. Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study). SITC 2022;Abstract 2409.
Schadendorf D et al. Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial. ESMO 2022;Abstract 784O.
Seth R et al. Systemic therapy for melanoma: ASCO guideline rapid recommendation update. J Clin Oncol 2022;40(21):2375-7. Abstract
Silk AW et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. J Immunother Cancer 2022;10(7):e004434. Abstract
Switzer B et al. Evolving management of stage IV melanoma. Am Soc Clin Oncol Educ Book 2023;43:e397478. Abstract
Tawbi HA et al. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. ASCO 2023;Abstract 9502.
Van Akkooi ACJ et al. Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design. ASCO 2023;Abstract TPS9601.
Weber JS et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected Stage IIIB-D or Stage IV melanoma (CheckMate 915). J Clin Oncol 2023;41(3):517-27. Abstract
Zuur CL et al. Towards organ preservation and cure via 2 infusions of immunotherapy only, in patients normally undergoing extensive and mutilating curative surgery for cutaneous squamous cell carcinoma: An investigator-initiated randomized phase II trial—The MATISSE trial. ASCO 2023;Abstract 9507.